[ad_1]
BENGALURU, India, January 21, 2026 /PRNewswire/ — Syngene International, a global contract research, development and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement expands the scope of integrated services across the drug development life cycle covering discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational science, pharmaceutical development and manufacturing, clinical trials, data and IT services to enable a seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, strengthening Syngene’s position as a strategic partner providing end-to-end integrated scientific and manufacturing solutions.
Peter Bains, Managing Director and CEO of Syngene International Ltd., said: “Our collaboration with Bristol Myers Squibb, now spanning more than 25 years, is rooted in scientific excellence, operational reliability and a shared commitment to advancing innovative therapies. The agreement to extend this partnership until 2035 allows us to plan together for the future in terms of building new capacity and infrastructure over a decade. Taking a long-term perspective is a key element of our partnership that adds strategic value to both companies. manufacturing programs that have the potential to improve outcomes for patients around the world.
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences, Bristol Myers Squibb, said, “At Bristol Myers Squibb, everything we do starts with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions.
The collaboration between Syngene and Bristol Myers Squibb began in 1998 and resulted in the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D center, which was fully commissioned in 2009. Over the years, the BBRC has become a major strategic R&D site for Bristol Myers Squibb, supporting integrated capabilities in target identification, lead discovery, optimization of leads, pharmaceutical development, molecular and cellular biology, protein sciences, testing biology and clinical biomarkers. The center, which today houses approximately 700 Syngene scientists working as an extension of Bristol Myers Squibb’s global research organization, contributes to discovery, preclinical development and patent filings in therapeutic areas such as cardiovascular disease, fibrosis, immunology and oncology.
Since its inception, the BBRC has played a pivotal role in accelerating the progression of new compounds from early discovery to first-in-human studies, helping to reduce development times and overall costs for Bristol Myers Squibb.
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries. Syngene’s team of more than 8,200 employees, including 5,600 scientists, brings both deep expertise and the ability to rapidly deliver scientific excellence, robust data security and world-class manufacturing to improve time to market and reduce the cost of innovation.
With more than 2.5 million square feet of specialized discovery, development and manufacturing facilities in India and the United States, Syngene works with 400 global customers across all industry segments, including biotechnology companies pursuing cutting-edge scientific research and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. To view the company’s latest environmental, social and governance (ESG) report, visit the Syngene ESG Report.
Media contacts:
Vijay Jeevandham
Syngene International Limited
M: +91 8310914552
E : Vijay.Jeevanandham@syngeneintl.com
Alex Heeley / Abdul Khalifeh
De facto communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E : a.khalifeh@defacto.co.uk
E : a.heeley@defacto.co.uk
SOURCE Syngene International
[ad_2]
Source: PR Newswire
